Sheba Medical Center Collaborates with Nuvo Intl. Group to Develop Advanced AI-Powered Remote Prenatal Care Solutions

RAMAT GAN, Israel – February 24, 2025 – ARC, the global health innovation engine and transformation arm of world-leading hospital Sheba Medical Center,  announced today a collaboration with Nuvo Intl. Group Inc. (Nuvo), a pioneer in remote pregnancy monitoring.Under the partnership, ARC and Nuvo will develop advanced AI-driven solutions that enhance clinical decision-making, improve early detection of pregnancy complications, and redefine the quality of continuous pregnancy monitoring, leading to improved maternal and fetal outcomes.

The collaboration will createAI-based modules that equip clinicians with advanced decision-support tools, enhance diagnostic capabilities, and enable early intervention. Additionally, population health analysis will be conducted to improve the quality of prenatal care in the community.

Nuvo’s remote monitoring solution enables expectant mothers to track their pregnancy conveniently from home, the workplace, or anywhere else, significantly improving the prenatal care experience and pregnancy outcomes. Under the direction of Dr. Avi Tsur, OB/GYN and high-risk pregnancy expert and Director of the Women’s HealthInnovation Center at Sheba Beyond, Sheba Medical Center’s virtual hospital, the collaboration will integrate medical research with Nuvo’s cutting-edge technology.

This agreement is part ofSheba's commitment to becoming one of the world’s first fully-integrated AI hospitals. Through ARC, Sheba is transforming healthcare by using AI to enhance patient care, diagnostics, and treatment personalization. As a leader in AI health tech, Sheba collaborates with top institutions like the Mayo Clinic to integrate advanced AI solutions across its departments, positioning itself at the forefront of medical innovation.

Prof. Eyal Zimlichman, Chief Transformation and Innovation Officer and Director of ARC at Sheba Medical Center, said: “Our partnership with Nuvo represents the future of pregnancy care. Integrating AI-powered solutions into routine prenatal monitoring not only enhances pregnancy outcomes but also demonstrates how technology can revolutionize healthcare worldwide.”

Laurence Klein, CEO of Nuvo Intl Group Inc., said: “We are excited to embark on this collaborative commercial and research partnership with Sheba’s ARC program, predicated on innovative, AI-driven modules powered by the INVU platform. Sheba ARC and ShebaBeyond’s global leadership in advancing remote and hybrid pregnancy care is invaluable, and we look forward to driving meaningful transformation together.”

About ARC

ARC, founded in 2019, is driving the redesign of global healthcare through a structured approach to innovation to equip all parts of the health ecosystem with the tools and resources to advance healthcare delivery and improve outcomes. Through ARC’s continuous pipeline of innovation, ability to facilitate large-scale transformation, access to leading health organizations, and ability to drive economic growth and development, ARC equips all player types in the ecosystem to transform global health. For more information, visit: https://arcinnovation.org

About Sheba Medical Center

The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer, is generating global impact through its medical care, research, and healthcare transformation. Sheba’s City of Health boasts acute-care, rehabilitation, children’s, cancer, and geriatric hospitals, research and innovation hubs, a medical simulation center, and a center for disaster response on one comprehensive campus in the center of Israel. Sheba serves as a true hospital without borders, welcoming users and healthcare professionals from all over the world and consistently providing the highest-level medical care to all in need. Sheba has been ranked a World’s Best Hospital by Newsweek six years in a row (2019–2024). For more information, visit: https://sheba-global.com/

About Nuvo Intl. Group

Nuvo is leading a transformation in pregnancy care by providing clinicians and expectant mothers with access to medically-necessary remote pregnancy monitoring anytime, anywhere. Nuvo’s INVU™ platform is an FDA-and CE-cleared remote pregnancy monitoring and management system. It enables the delivery of remote non-stress tests (NSTs) and maternal and fetal heart rate monitoring while pioneering new data-driven personalized pathways that Nuvo believes can improve future health outcomes. INVU is being used by leading health providers and research institutions across the US and Israel. Nuvo plans to continue to expand the footprint of sales in the US and Israel to provide remote access and insights not previously deemed possible, while preparing for its market entry into Europe. Nuvo is led by a diverse team of experienced business, medical, and technology leaders, united in the mission of breaking down barriers to pregnancy care to give every life abetter beginning. For more information and complete indications, contraindications, warnings and precautions, and instructions for use, visit www.nuvocares.com

‍

The information contained in this press release is for informational purposes only and is not intended to serve as financial, legal, or investment advice. The content provided herein is based on current data as of the date of publication and is subject to change without notice.  This information may contain forward-looking statements, which include but are not limited to projections, plans, objectives, and future performance or assumptions underlying such statements. These statements are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied herein. Nuvo Intl. Group Inc. does not guarantee the accuracy, completeness, or timeliness of the information provided and expressly disclaims any liability for errors or omissions. Certain information has been provided by third-party sources and, although believed to be reliable, it has not been independently verified and its accuracy or completeness cannot be guaranteed.  Past performance is not indicative of future results. This information does not constitute an offer to sell or a solicitation to buy any securities or other financial instruments.

‍